Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $30.60 | Total: $153.00 |
| 1 | 10 | $25.92 | Total: $259.20 |
| 1 | 25 | $21.96 | Total: $549.00 |
| 1 | 50 | $18.72 | Total: $936.00 |
| 1 | 100 | $16.20 | Total: $1,620.00 |
Overview
Ro5-3335 (CBF?-Runx1 inhibitor II) is core binding factor (CBF) inhibitor; preferentially kills human leukemia cell lines with CBF fusion proteins (IC50 = 1.1 ?M). Ro5-3335 represses RUNX1CBF?-dependent transactivation in reporter assays and inhibits transcriptional regulation by RUNX1 and CBF?. Ro5-3335 also reduces the leukemia burden in a mouse model. Attenuates RUNX1-dependent hematopoiesis in zebrafish embryos. It also is a Tat antagonist and inhibits HIV-1 replication in vitro.
Chemical Properties
| Molecular Formula | C13H10ClN3O |
| Molecular Weight | 259.69 |
| CAS Numbers | 30195-30-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | Clc1ccc2NC(=O)CN=C(c3ccc[nH]3)c2c1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Cunningham L, et al.Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBF? interaction.Proc Natl Acad Sci U S A. 2012 Sep 4;109[36] 14592-7.